CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance
NCT ID: NCT03525639
Last Updated: 2025-05-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-12-06
Study Completion Date
2021-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with acute myocarditis (AM) usually experience spontaneous healing, but a considerable percentage of them evolve towards chronic long-term cardiac impairment. The evolution towards dilated cardiomyopathy (DCM) occurs in a subtle manner, frequently after an initial recover that mimics complete healing. Differences in the course of the disease may reflect the course of underlying myocardial inflammation related to viral clearance or persistence and to the following autoimmune response.
Cardiac magnetic resonance (CMR) mapping parameters have been developed for the quantification of edema and necrosis, showing high diagnostic accuracy. No mapping parameter has been developed for the assessment of the third Lake Louise criteria, namely the hyperemia, and, furthermore, their prognostic role is not completely understood.
The study hypothesis is that the early-enhanced T1 mapping parameter may have great diagnostic accuracy for myocarditis, and that a short-term monitoring with a complete CMR protocol at 2 month after symptoms onset may identify the subgroup of patients at high risk of progression towards DCM.
The results of this study will help to significantly improve diagnostic performances of CMR and may help to manage patients with AM.
Cardiac magnetic resonance (CMR) mapping parameters have been developed for the quantification of edema and necrosis, showing high diagnostic accuracy. No mapping parameter has been developed for the assessment of the third Lake Louise criteria, namely the hyperemia, and, furthermore, their prognostic role is not completely understood.
The study hypothesis is that the early-enhanced T1 mapping parameter may have great diagnostic accuracy for myocarditis, and that a short-term monitoring with a complete CMR protocol at 2 month after symptoms onset may identify the subgroup of patients at high risk of progression towards DCM.
The results of this study will help to significantly improve diagnostic performances of CMR and may help to manage patients with AM.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical, Morphological and Functional Aspects in Myocarditis.
NCT04217876
Myocarditis
COMPLETED
CMR Features in Patients With Suspected Myocarditis
NCT03470571
Outcome, Fatal
COMPLETED
Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management
NCT04521790
Myocarditis
Ventricular Arrythmia
Inflammatory Cardiomyopathy
+6 more
RECRUITING
Evaluation of Spectral Cardiac CT for the Diagnosis of Acute Myocarditis
NCT02905721
Patients With Suspected Acute Myocarditis
UNKNOWN
NA
EARLY-MYO-Myocarditis Registry
NCT04338113
Myocarditis
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background and Significance:
In patients with acute myocarditis (AM), spontaneous improvement can be observed in the majority of cases, but progression towards dilated cardiomyopathy (DCM) is a not rare outcome (around 20% of patients) (Feldmann N Engl J Med 2000;343:1388-98). Differences in the course of the disease may reflect the course of the underlying viral infection. In a large series of patients with AM submitted to two endo-myocardial biopsies (EMBs) in few months, Kuhl demonstrated that viral clearance was associated with spontaneous ejection fraction (EF) improvement, while EF did not improve or even deteriorated in patients with viral and myocardial inflammation persistence (Kühl Circulation 2005;111:887-93. Kühl Circulation 2005;112:1965-70). However, repeated EMBs cannot be proposed in the clinical routine and, hence, non-invasive detection of the subgroup of patients with inflammation persistence should have important implications. Today, cardiac magnetic resonance (CMR) is recognized as an accurate non-invasive imaging tool to diagnose acute myocarditis, because of its ability to detect myocardial inflammation and necrosis (Friedrich J Am Coll Cardiol 2009;53:1475-87).
The introduction of mapping techniques has significantly improved CMR sensitivity, allowing to detect both focal and diffuse involvement, with a substantial benefit in the convalescent phase where conventional Lake Louise criteria often fail.
However, no technical development has been performed for the evaluation of Early Gadolinium Enhancement (EGE), which continues to be assessed on T1-w images, being the less robust Lake Louise criteria and eliminated from the updated Lake Louise criteria \[Ferreira J Am Coll Cardiol 2018;72(24):3158-76.\].
Therefore, there are two major clinical needs: (a) the first being the improvement in diagnosis fulfilling the lack in technical advancement in the setting of EGE evaluation, (b) the second being risk-stratification and prediction of prognosis. The study hypothesis is that the development of a quantitative method based on T1 mapping for the assessment of EGE may be highly sensitive and specific for the diagnosis of myocarditis. Then, the assessment of early changes in CMR parameters at a short-term CMR study (2 months after symptoms onset) may have great value in outcome prediction.
Preliminary data: A previous study performed on patients with chronic inflammatory cardiomyopathy demonstrated that the positivity of CMR parameters of necrosis (LGE) and inflammation (oedema) is significantly higher in patients with an active inflammation at EMB, compared to patients with borderline histological criteria (De Cobelli 2006 JACC;47:1649-54). These data suggest the possibility to detect with CMR the persistence of subtle myocardial inflammation after the acute phase in patients with myocarditis.
Moreover, Wagner and Colleagues demonstrated, in a small group of patients, a correlation between CMR evidence of myocardial hyperaemia persistence 4 weeks after the onset of acute myocarditis and negative left ventricular (LV) remodelling 30 months later (Wagner A 2003 MAGMA;16:17-20).
Materials and Methods:
This is a prospective multicentre cohort study. 80 patients with diagnosis of acute myocarditis (AM) will be enrolled.
All patients admitted to Hospital with suspect of AM will be submitted to:
collection of detailed anamnesis and physical examination, 12-lead ECG, laboratory exams, transthoracic echocardiography, coronary catheterization or coronary computed tomography (CT) angiography when an ischemic cause of symptoms need to be excluded and CMR imaging within 3-5 days.
CMR protocol will include Lake-Louise criteria, parametric mappings (native T1, T2 mapping and ECV), with an additional early-enhanced T1 mapping acquired 2 minutes after gadolinium injection.
All patients with clinically or EMB confirmed diagnosis of AM will be enrolled and will undergo a second CMR study 2 month later.
All patients will undergo a clinical/instrumental follow-up including: CMR assessment of LV ejection fraction and end-diastolic volume after at least 1 year from diagnosis; registration of all-cause mortality, cardiac death and aborted cardiac sudden death in patients with implantable cardioverter-defibrillator (ICD).
Impact and Translational Implications:
Myocarditis is characterized by significant heterogeneity of long-term evolution. CMR could play a key role in the non-invasive and early identification of patients with persistent myocardial inflammation, at high risk to evolve towards an irreversible post-myocarditis heart failure. Thus, CMR may help to design tailored management of patients. In this perspective, invasive characterization of damage mechanism and aetiology might be reserved to patients with CMR evidence of inflammation persistence.
In patients with acute myocarditis (AM), spontaneous improvement can be observed in the majority of cases, but progression towards dilated cardiomyopathy (DCM) is a not rare outcome (around 20% of patients) (Feldmann N Engl J Med 2000;343:1388-98). Differences in the course of the disease may reflect the course of the underlying viral infection. In a large series of patients with AM submitted to two endo-myocardial biopsies (EMBs) in few months, Kuhl demonstrated that viral clearance was associated with spontaneous ejection fraction (EF) improvement, while EF did not improve or even deteriorated in patients with viral and myocardial inflammation persistence (Kühl Circulation 2005;111:887-93. Kühl Circulation 2005;112:1965-70). However, repeated EMBs cannot be proposed in the clinical routine and, hence, non-invasive detection of the subgroup of patients with inflammation persistence should have important implications. Today, cardiac magnetic resonance (CMR) is recognized as an accurate non-invasive imaging tool to diagnose acute myocarditis, because of its ability to detect myocardial inflammation and necrosis (Friedrich J Am Coll Cardiol 2009;53:1475-87).
The introduction of mapping techniques has significantly improved CMR sensitivity, allowing to detect both focal and diffuse involvement, with a substantial benefit in the convalescent phase where conventional Lake Louise criteria often fail.
However, no technical development has been performed for the evaluation of Early Gadolinium Enhancement (EGE), which continues to be assessed on T1-w images, being the less robust Lake Louise criteria and eliminated from the updated Lake Louise criteria \[Ferreira J Am Coll Cardiol 2018;72(24):3158-76.\].
Therefore, there are two major clinical needs: (a) the first being the improvement in diagnosis fulfilling the lack in technical advancement in the setting of EGE evaluation, (b) the second being risk-stratification and prediction of prognosis. The study hypothesis is that the development of a quantitative method based on T1 mapping for the assessment of EGE may be highly sensitive and specific for the diagnosis of myocarditis. Then, the assessment of early changes in CMR parameters at a short-term CMR study (2 months after symptoms onset) may have great value in outcome prediction.
Preliminary data: A previous study performed on patients with chronic inflammatory cardiomyopathy demonstrated that the positivity of CMR parameters of necrosis (LGE) and inflammation (oedema) is significantly higher in patients with an active inflammation at EMB, compared to patients with borderline histological criteria (De Cobelli 2006 JACC;47:1649-54). These data suggest the possibility to detect with CMR the persistence of subtle myocardial inflammation after the acute phase in patients with myocarditis.
Moreover, Wagner and Colleagues demonstrated, in a small group of patients, a correlation between CMR evidence of myocardial hyperaemia persistence 4 weeks after the onset of acute myocarditis and negative left ventricular (LV) remodelling 30 months later (Wagner A 2003 MAGMA;16:17-20).
Materials and Methods:
This is a prospective multicentre cohort study. 80 patients with diagnosis of acute myocarditis (AM) will be enrolled.
All patients admitted to Hospital with suspect of AM will be submitted to:
collection of detailed anamnesis and physical examination, 12-lead ECG, laboratory exams, transthoracic echocardiography, coronary catheterization or coronary computed tomography (CT) angiography when an ischemic cause of symptoms need to be excluded and CMR imaging within 3-5 days.
CMR protocol will include Lake-Louise criteria, parametric mappings (native T1, T2 mapping and ECV), with an additional early-enhanced T1 mapping acquired 2 minutes after gadolinium injection.
All patients with clinically or EMB confirmed diagnosis of AM will be enrolled and will undergo a second CMR study 2 month later.
All patients will undergo a clinical/instrumental follow-up including: CMR assessment of LV ejection fraction and end-diastolic volume after at least 1 year from diagnosis; registration of all-cause mortality, cardiac death and aborted cardiac sudden death in patients with implantable cardioverter-defibrillator (ICD).
Impact and Translational Implications:
Myocarditis is characterized by significant heterogeneity of long-term evolution. CMR could play a key role in the non-invasive and early identification of patients with persistent myocardial inflammation, at high risk to evolve towards an irreversible post-myocarditis heart failure. Thus, CMR may help to design tailored management of patients. In this perspective, invasive characterization of damage mechanism and aetiology might be reserved to patients with CMR evidence of inflammation persistence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myocarditis Acute
Myocardial Inflammation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Acute Myocarditis
Patients undergoing Cardiac Magnetic Resonance at baseline, 2 month, 1 year.
Group Type
EXPERIMENTAL
Cardiac Magnetic Resonance
Intervention Type
DIAGNOSTIC_TEST
Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac Magnetic Resonance
Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of at least 1 of the subsequent clinical features \[12\]:
* Acute chest pain (pericarditic, or pseudo-ischaemic)
* New-onset dyspnoea at rest or during exercise
* Fatigue with or without left/right heart failure signs
* Palpitation or unexplained arrhythmia symptoms or syncope or aborted sudden cardiac death
* Unexplained cardiogenic shock
* Associated with at least 1 of the subsequent diagnostic criteria \[12\]:
* Newly abnormal 12 lead ECG and/or Holter and/or stress testing, any of the following: I to III degree atrioventricular block, or bundle branch block, ST/T wave change, sinus arrest, ventricular tachycardia or fibrillation and asystole, atrial fibrillation, reduced R wave height, intraventricular conduction delay, abnormal Q waves, low voltage, frequent premature beats, supraventricular tachycardia
* Myocardial injury markers (elevated troponin T/Troponin I)
* New, otherwise unexplained left ventricular (LV) and/or right ventricular (RV) functional and/or structural abnormalities on cardiac imaging (echo/angio/CMR) compatible with acute myocarditis and excluding other diseases
* Signed informed consent
* Acute chest pain (pericarditic, or pseudo-ischaemic)
* New-onset dyspnoea at rest or during exercise
* Fatigue with or without left/right heart failure signs
* Palpitation or unexplained arrhythmia symptoms or syncope or aborted sudden cardiac death
* Unexplained cardiogenic shock
* Associated with at least 1 of the subsequent diagnostic criteria \[12\]:
* Newly abnormal 12 lead ECG and/or Holter and/or stress testing, any of the following: I to III degree atrioventricular block, or bundle branch block, ST/T wave change, sinus arrest, ventricular tachycardia or fibrillation and asystole, atrial fibrillation, reduced R wave height, intraventricular conduction delay, abnormal Q waves, low voltage, frequent premature beats, supraventricular tachycardia
* Myocardial injury markers (elevated troponin T/Troponin I)
* New, otherwise unexplained left ventricular (LV) and/or right ventricular (RV) functional and/or structural abnormalities on cardiac imaging (echo/angio/CMR) compatible with acute myocarditis and excluding other diseases
* Signed informed consent
Exclusion Criteria
* History of cardiomyopathies
* Coronary artery disease (coronary catheterization or CT angiography will be performed when coronary artery disease need to be excluded in consideration of signs and symptoms)
* ICD or pacemaker
* Inability to hold breath or to lay down for 45 min
* Claustrophobia
* Recent history of alimentary/alcoholic/respiratory intoxication
* CMR diagnostic criteria suggestive of other cardiac disease explaining signs and symptoms (e.g. myocardial infarction with patent coronary arteries, tako-tsubo syndrome)
* Risk for nephrogenic systemic fibrosis (estimated glomerular filtration rate \< 30 mL/min/1.73 m2)
* History of allergic reaction to MR contrast media
* Pregnancy or breast-feeding
* Coronary artery disease (coronary catheterization or CT angiography will be performed when coronary artery disease need to be excluded in consideration of signs and symptoms)
* ICD or pacemaker
* Inability to hold breath or to lay down for 45 min
* Claustrophobia
* Recent history of alimentary/alcoholic/respiratory intoxication
* CMR diagnostic criteria suggestive of other cardiac disease explaining signs and symptoms (e.g. myocardial infarction with patent coronary arteries, tako-tsubo syndrome)
* Risk for nephrogenic systemic fibrosis (estimated glomerular filtration rate \< 30 mL/min/1.73 m2)
* History of allergic reaction to MR contrast media
* Pregnancy or breast-feeding
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Italy
OTHER_GOV
Sponsor Role
collaborator
Antonio Esposito
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Esposito
Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonio Esposito
Role: PRINCIPAL_INVESTIGATOR
IRCCS San Raffaele
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS San Raffaele
Milan, , Italy
Site Status
Policlinico Umberto I
Roma, , Italy
Site Status
AOU Città della Salute e della Scienza
Torino, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Youn JC, Shim HS, Lee JS, Ji AY, Oh J, Hong N, Lee HS, Park S, Lee SH, Choi D, Chung N, Kang SM. Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis. Cardiovasc Pathol. 2014 May-Jun;23(3):139-44. doi: 10.1016/j.carpath.2014.01.004. Epub 2014 Jan 17.
Reference Type
BACKGROUND
Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, Salvi A, Perkan A, Di Lenarda A, Bussani R, Bartunek J, Sinagra G. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation. 2013 Nov 26;128(22):2384-94. doi: 10.1161/CIRCULATIONAHA.113.003092. Epub 2013 Oct 1.
Reference Type
BACKGROUND
Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012 Feb 25;379(9817):738-47. doi: 10.1016/S0140-6736(11)60648-X. Epub 2011 Dec 18.
Reference Type
BACKGROUND
Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation. 2005 Feb 22;111(7):887-93. doi: 10.1161/01.CIR.0000155616.07901.35. Epub 2005 Feb 7.
Reference Type
BACKGROUND
Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005 Sep 27;112(13):1965-70. doi: 10.1161/CIRCULATIONAHA.105.548156. Epub 2005 Sep 19.
Reference Type
BACKGROUND
Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009 Apr 28;53(17):1475-87. doi: 10.1016/j.jacc.2009.02.007.
Reference Type
BACKGROUND
Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006 Oct 10;114(15):1581-90. doi: 10.1161/CIRCULATIONAHA.105.606509. Epub 2006 Oct 2.
Reference Type
BACKGROUND
Natale L, De Vita A, Baldari C, Meduri A, Pieroni M, Lombardo A, Crea F, Bonomo L. Correlation between clinical presentation and delayed-enhancement MRI pattern in myocarditis. Radiol Med. 2012 Dec;117(8):1309-19. doi: 10.1007/s11547-012-0790-x. Epub 2012 Feb 10. English, Italian.
Reference Type
BACKGROUND
Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert EM, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U, Mahrholdt H. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012 May 1;59(18):1604-15. doi: 10.1016/j.jacc.2012.01.007. Epub 2012 Feb 22.
Reference Type
BACKGROUND
Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210. Epub 2013 Jul 3.
Reference Type
BACKGROUND
De Cobelli F, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, Canu T, Perseghin G, Gaudio C, Maseri A, Frustaci A, Del Maschio A. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006 Apr 18;47(8):1649-54. doi: 10.1016/j.jacc.2005.11.067. Epub 2006 Mar 29.
Reference Type
BACKGROUND
Wagner A, Schulz-Menger J, Dietz R, Friedrich MG. Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic paragraph sign resonance imaging. MAGMA. 2003 Feb;16(1):17-20. doi: 10.1007/s10334-003-0007-7.
Reference Type
BACKGROUND
Francone M, Chimenti C, Galea N, Scopelliti F, Verardo R, Galea R, Carbone I, Catalano C, Fedele F, Frustaci A. CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging. 2014 Mar;7(3):254-63. doi: 10.1016/j.jcmg.2013.10.011. Epub 2014 Feb 19.
Reference Type
BACKGROUND
Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009 Aug;30(16):1995-2002. doi: 10.1093/eurheartj/ehp249. Epub 2009 Jun 25.
Reference Type
BACKGROUND
Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, Di Meglio F, Nadal-Ginard B, Frustaci A, Leri A, Maseri A, Anversa P. Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res. 2003 Oct 3;93(7):604-13. doi: 10.1161/01.RES.0000093985.76901.AF. Epub 2003 Sep 4.
Reference Type
BACKGROUND
Yeon SB, Salton CJ, Gona P, Chuang ML, Blease SJ, Han Y, Tsao CW, Danias PG, Levy D, O'Donnell CJ, Manning WJ. Impact of age, sex, and indexation method on MR left ventricular reference values in the Framingham Heart Study offspring cohort. J Magn Reson Imaging. 2015 Apr;41(4):1038-45. doi: 10.1002/jmri.24649. Epub 2014 May 12.
Reference Type
BACKGROUND
Luetkens JA, Doerner J, Thomas DK, Dabir D, Gieseke J, Sprinkart AM, Fimmers R, Stehning C, Homsi R, Schwab JO, Schild H, Naehle CP. Acute myocarditis: multiparametric cardiac MR imaging. Radiology. 2014 Nov;273(2):383-92. doi: 10.1148/radiol.14132540. Epub 2014 Jun 6.
Reference Type
BACKGROUND
Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003 Oct 15;60(1):5-10. doi: 10.1016/s0008-6363(03)00437-1.
Reference Type
BACKGROUND
Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003 Jun 10;107(22):2793-8. doi: 10.1161/01.CIR.0000072766.67150.51. Epub 2003 May 27.
Reference Type
BACKGROUND
Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003 Feb 18;107(6):857-63. doi: 10.1161/01.cir.0000048147.15962.31.
Reference Type
BACKGROUND
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176. doi: 10.1016/j.jacc.2018.09.072.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIAMI GR-2013-02356832
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers
NCT02823886
COMPLETED
NA
MRI Evaluation of Chest Pain
NCT00001961
COMPLETED
PHASE2
Role of Spectral CT in the Diagnosis of Myocarditis/MINOCA in Patients Undergoing cardioCT Investigations for Acute Chest Pain
NCT06804278
RECRUITING
Stress Multidetector Computed Tomography (MDCT) an New Diagnostic Tool for Myocardial Disease
NCT00949520
COMPLETED
NA
Relationship Between CMR-derived Parameters of Ischemia / Reperfusion Injury and Timing of CMR in STEMI
NCT03522116
COMPLETED
Dynamic CT Myocardial Perfusion Imaging
NCT02593838
TERMINATED
NA
Follow-up of the Cardiomyopathy Cohort SFB/TR19
NCT02971267
RECRUITING
Diagnostics for the Reperfusion Injury Following MI
NCT00529607
COMPLETED
Early Cardiac Magnetic Resonance Imaging in Suspected Non-ST-Elevation Myocardial Infarction
NCT04140019
UNKNOWN
Myocardial Ischemia Detection With a Combined Cardiovascular Magnetic Resonance and Biomarker Protocol
NCT05813210
NOT_YET_RECRUITING
NA
Analysis of Cardiac Damage Post Infection With SARS-CoV-2 and Post Vaccination Against COVID-19
NCT05124223
COMPLETED
MYocardial DOmmages Related to COVID-19
NCT04498065
COMPLETED
Stress Cardiac MRI in Ischemic Patients
NCT04588675
UNKNOWN
Coronary Physiology Testing in Acute Coronary Syndromes
NCT04677257
COMPLETED
NA
Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients
NCT04358952
COMPLETED
Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort
NCT06898762
RECRUITING
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
NCT07093528
ENROLLING_BY_INVITATION
Lymphatic Organs and Myocardium After Myocardial Infarction
NCT05519735
RECRUITING
NA
Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction
NCT02649517
UNKNOWN
NA
Role of Stress CMR in Predicting Adverse Clinical Events in Patients With Known or Suspected IHD
NCT01821924
COMPLETED
Prognostic Role of High Sensitivity Troponin During Follow up in the Evolution of Acute Myocarditis
NCT05949450
NOT_YET_RECRUITING
Randomized Investigation of Chest Pain Diagnostic Strategies
NCT01035047
COMPLETED
NA
Dobutamine vs Adenosine CMR Study
NCT03661827
COMPLETED
NA
Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo
NCT00575549
NO_LONGER_AVAILABLE
Characterization of Patients With Post-ischemic Left Ventricular Dysfunction
NCT04699565
COMPLETED